anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

130,561-130,620 of 319,975

filter-aware
233
The slide uses a Q&A transcript format to validate the activist's thesis regarding data manipulation and competitive threat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
234
The slide uses a long, narrative-style headline that summarizes the ex-employee's critique, followed by a highlighted block quote.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
235
The slide uses Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
236
The slide uses a direct quote from an ex-employee to undermine the clinical value proposition of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
237
The slide uses a Q&A format to frame the contradiction between weight loss goals and diabetes risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
238
The slide uses direct quotes from an ex-employee to undermine the credibility of the company's clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
239
The slide uses a Q&A format to highlight specific concerns about data collection consistency and physiological noise (edema).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
240
The slide uses a Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
241
The slide uses a quote to establish credibility and validate the activist's research findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
242
The slide uses direct quotes from a Key Opinion Leader (KOL) to build a case against the drug's safety and market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
243
The slide uses a Q&A format to validate the primary claim made in the headline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
244
The slide uses direct quotes to build a case of corporate malfeasance regarding safety disclosures.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
245
The slide uses a 'quote-summary' structure to undermine the company's launch narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
246
The slide uses a Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
247
The slide uses a Q&A transcript format to build a case against the safety of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
248
The slide uses a Q&A transcript format to highlight potential safety concerns and lack of transparency regarding trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
249
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
250
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
251
The slide uses a Q&A format to highlight inconsistencies in clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
252
The slide uses direct quotes from a KOL to undermine the company's marketing narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
253
The slide uses a quote to undermine the credibility of the company's clinical trial data by highlighting the difference between controlled trial environments and real-world application.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
254
The slide uses direct quotes to frame the problem of insurance access as a deliberate strategy of 'playing chicken' by insurers.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
255
The slide uses direct quotes to frame the company's actions as predatory and unethical.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
256
The slide uses direct quotes from a KOL to frame the company's town hall as an 'infomercial' that avoids difficult questions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
257
The slide uses a Q&A format to present expert testimony that undermines the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
258
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
259
The slide uses a 'Miller XR' moniker to highlight the perceived over-reliance on a single individual.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
260
The slide uses red boxes to highlight the name 'Jennifer Miller' across different study documents to emphasize her consistent involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
261
The slide uses a quote to highlight potential ethical or professional concerns regarding a physician's promotion of a drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
262
The slide uses emotional imagery and anecdotal evidence to undermine the credibility of a key figure in the PWS space.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
263
Includes a screenshot of a blog post and two photos of the doctor interacting with a child.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
264
The slide uses direct quotes and expert testimony to build a case against the credibility of a key opinion leader (Miller).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
265
The slide uses a screenshot of a tweet as primary evidence to expose the subject's promotional behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
266
Uses press release excerpts to establish a pattern of behavior or conflict of interest.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
267
The slide uses a combination of narrative text, a screenshot of a YouTube video, and snippets of press articles to build a case of poor judgment or questionable association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
268
The slide uses a direct quote to highlight a conflict of interest or professional disagreement regarding medical standards.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
269
The slide uses direct quotes from an Anthem VP to undermine the product's market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
270
The slide uses highlighted text to emphasize key parts of the expert interview transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
271
The slide uses direct quotes to expose the insurer's strategy of forcing generic/compounded substitution to save costs.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
272
The slide uses red arrows to connect the two associations to the town hall event flyer.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
273
The slide uses expert quotes to undermine the perceived market opportunity for Soleno.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
274
The slide uses a Q&A transcript format to undermine the commercial viability of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
275
The slide uses direct quotes from a researcher to undermine the perceived positive sentiment of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
276
The slide uses a Q&A format to highlight the tension between corporate marketing pressure and scientific/ethical boundaries.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
277
The slide uses a Q&A format to highlight negative expert sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
278
The slide uses a Q&A format to highlight negative expert sentiment regarding commercial viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
279
The slide uses highlighted quotes from a former senior medical affairs employee to undermine the commercial viability of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
280
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
281
The slide uses a 'villain/expert critique' format to undermine the target company's drug efficacy and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
282
The slide uses highlighted text to draw attention to key negative sentiments from the KOL.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
283
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
284
The slide uses a Q&A transcript format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
285
The slide uses a Q&A format to present expert opinion as evidence of safety risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
286
The slide uses highlighted text to emphasize key concerns about cardiac risk, genetic subtypes, and the drug's unknown mechanism of action.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
287
The slide highlights a potential safety risk identified by a KOL regarding the drug's mechanism of action.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
288
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug Vykat, specifically highlighting the risk of electrolyte depletion when combined with diuretics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
289
Uses Q&A format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
290
The slide uses a Q&A format to highlight allegations of 'artificial enrollment' and data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
291
Uses direct quotes from a trial investigator to undermine the validity of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
292
The slide uses a Q&A format to highlight allegations of data manipulation and lack of clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit